RxDoctor Payments Data

Thomas Isaacson, MD

Cardiovascular Disease · Las Vegas, NVNPI 1104884311

Payments from drug & device makers

$2,763in general payments, 2019–2025

Across 26 payments — averaging $106.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$3K
  • Johnson & Johnson$42
  • Alnylam Pharmaceuticals Inc.$22
  • Heartflow, Inc.$21
  • Novartis$21
  • Chiesi USA, Inc.$20
  • plus $51 from 3 others

What the payments were for

  • Travel & lodging$1,71662%
  • Food & beverage$1,04738%

General payments by program year

19
20
21
22
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,763 in reported general payments places this provider in the 45th percentile of 165 cardiovascular disease providers in Nevada.

See all cardiovascular disease providers in Nevada

Medicare billing

Part B allowed, 2024
$92,715
Medicare patients
414
Services billed
968

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban276$232,176
EntrestoSacubitril/Valsartan37$42,883
JardianceEmpagliflozin35$32,588
XareltoRivaroxaban19$26,708
Metoprolol Succinate311$3,824
Diltiazem 24hr Er (Cd)Diltiazem Hcl43$2,144
Valsartan77$1,293
Atorvastatin Calcium146$1,082
Ezetimibe77$915
ClopidogrelClopidogrel Bisulfate123$859
Spironolactone176$859
Ranolazine ErRanolazine14$776
Rosuvastatin Calcium111$767
Bumetanide20$648
Furosemide95$456

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$21$42,88337 claims
Johnson & JohnsonXarelto$42$26,70819 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 165 cardiovascular disease providers in Nevada.

Other cardiovascular disease in Las Vegas

See the full list for Nevada

Where these figures come from

Is this you, or does something look wrong? →